How, When, and For Whom Should We Perform Therapeutic Drug Monitoring?

[1]  D. Franchimont,et al.  Effect of vedolizumab dose intensification on serum drug concentrations and regain of response in inflammatory bowel disease patients with secondary loss of response , 2021, GastroHep.

[2]  S. Vermeire,et al.  Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's Disease. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  B. Weiss,et al.  Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children with Crohn's Disease Compared with Reactive Monitoring. , 2019, Gastroenterology.

[4]  N. Mostafavi,et al.  Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease. , 2019, Gastroenterology.

[5]  S. Vermeire,et al.  Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study. , 2019, Journal of Crohn's & colitis.

[6]  G. Kaplan,et al.  Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[7]  W. Sandborn,et al.  Infliximab Exposure-Response Relationship and Thresholds Associated With Endoscopic Healing in Patients With Ulcerative Colitis. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[8]  S. Vermeire,et al.  Ustekinumab exposure-outcome analysis in Crohn's disease only in part explains limited endoscopic remission rates. , 2019, Journal of Crohn's & colitis.

[9]  J. Lambert,et al.  Clinical response correlates with 4‐week postinjection ustekinumab concentrations in patients with moderate‐to‐severe psoriasis† , 2019, The British journal of dermatology.

[10]  A. Gonçalves,et al.  Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease. , 2019, Inflammatory bowel diseases.

[11]  E. Laserna-Mendieta,et al.  Comparison of a new rapid method for the determination of adalimumab serum levels with two established ELISA kits , 2019, Clinical chemistry and laboratory medicine.

[12]  M. Parkes,et al.  Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. , 2019, The lancet. Gastroenterology & hepatology.

[13]  P. Bossuyt,et al.  Tu1818 – Ultra-Proactive Therapeutic Drug Monitoring Incorporating Infliximab Point-Of-Care Testing with Ad Hoc Dose Adjustment Reduces C-Reactive Protein Levels in Patients with IBD During Infliximab Maintenance Treatment , 2019, Gastroenterology.

[14]  Marien González-Lorenzo,et al.  Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn's Disease or Ulcerative Colitis: A Systematic Review and Meta‐analysis , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[15]  B. Flourié,et al.  Concentrations of Ustekinumab During Induction Therapy Associate With Remission in Patients With Crohn's Disease. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[16]  D. Mould,et al.  DOP56 Dashboard driven vs. conventional dosing of infliximab in inflammatory bowel disease patients: the PRECISION trial , 2019, Journal of Crohn's and Colitis.

[17]  B. Vaughn,et al.  Proactive therapeutic drug monitoring of adalimumab is associated with better long-term outcomes compared to standard of care in patients with inflammatory bowel disease. , 2019, Journal of Crohn's & colitis.

[18]  M. Gastonguay,et al.  Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation , 2019, Alimentary pharmacology & therapeutics.

[19]  C. Brochard,et al.  Predictors of relapse following infliximab de‐escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring , 2019, Alimentary pharmacology & therapeutics.

[20]  A. Cheifetz,et al.  Association Between Serum Infliximab Trough Concentrations During Maintenance Therapy and Biochemical, Endoscopic, and Histologic Remission in Crohn's Disease. , 2018, Inflammatory bowel diseases.

[21]  Yow-Ming C Wang,et al.  Individualized Dosing of Therapeutic Monoclonal Antibodies—a Changing Treatment Paradigm? , 2018, The AAPS Journal.

[22]  S. Vermeire,et al.  Influence of early adalimumab serum levels on immunogenicity and long‐term outcome of anti‐TNF naive Crohn's disease patients: the usefulness of rapid testing , 2018, Alimentary pharmacology & therapeutics.

[23]  Ravy K. Vajravelu,et al.  Proactive Infliximab Monitoring Following Reactive Testing is Associated With Better Clinical Outcomes Than Reactive Testing Alone in Patients With Inflammatory Bowel Disease , 2018, Journal of Crohn's & colitis.

[24]  X. Roblin,et al.  Comparison of Point-of-Care and Classical Immunoassays for the Monitoring Infliximab and Antibodies Against Infliximab in IBD , 2018, Digestive Diseases and Sciences.

[25]  D. Mould,et al.  Prediction of Individual Serum Infliximab Concentrations in Inflammatory Bowel Disease by a Bayesian Dashboard System , 2018, Journal of clinical pharmacology.

[26]  R. Eliakim,et al.  Prospective Observational Evaluation of Time‐Dependency of Adalimumab Immunogenicity and drug concentrations: the POETIC Study , 2018, The American Journal of Gastroenterology.

[27]  R. Boshuizen,et al.  Capillary blood microsampling to determine serum biopharmaceutical concentration: Mitra® microsampler vs dried blood spot. , 2018, Bioanalysis.

[28]  S. Hanauer,et al.  Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease. , 2018, Gastroenterology.

[29]  M. Dubinsky,et al.  Mo1838 - Pharmacokinetic Dashboard-Driven Infliximab Dosing in IBD:A Prospective Interventional Study , 2018 .

[30]  D. Franchimont,et al.  Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease. , 2018, Gastroenterology.

[31]  L. Peyrin-Biroulet,et al.  Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study , 2018, Alimentary pharmacology & therapeutics.

[32]  M. Dubinsky,et al.  Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care? , 2018, Gastroenterology.

[33]  R. Eliakim,et al.  Early drug and anti‐infliximab antibody levels for prediction of primary nonresponse to infliximab therapy , 2018, Alimentary pharmacology & therapeutics.

[34]  S. Vermeire,et al.  Exposure‐response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease , 2017, Alimentary pharmacology & therapeutics.

[35]  K. Farkas,et al.  Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort , 2017, Inflammatory bowel diseases.

[36]  J. Andrews,et al.  Review article: consensus statements on therapeutic drug monitoring of anti‐tumour necrosis factor therapy in inflammatory bowel diseases , 2017, Alimentary pharmacology & therapeutics.

[37]  A. Gils,et al.  Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases , 2017, Clinical pharmacology : advances and applications.

[38]  Ravy K. Vajravelu,et al.  Improved Long‐term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[39]  T. Matsui,et al.  Significance of measurement of serum trough level and anti‐drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial , 2017, Alimentary pharmacology & therapeutics.

[40]  Siddharth Singh,et al.  American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases. , 2017, Gastroenterology.

[41]  B. Ryan,et al.  Positive relationship between infliximab and adalimumab trough levels at completion of induction therapy with clinical response rates, at a tertiary referral center , 2017, JGH open : an open access journal of gastroenterology and hepatology.

[42]  Siddharth Singh,et al.  American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. , 2017, Gastroenterology.

[43]  A. Gonçalves,et al.  Clinical performance of an infliximab rapid quantification assay , 2017, Therapeutic advances in gastroenterology.

[44]  S. Vermeire,et al.  Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial , 2017, Gut.

[45]  M. Abreu,et al.  Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease , 2017, Alimentary pharmacology & therapeutics.

[46]  S. Vermeire,et al.  Rapid Test for Infliximab Drug Concentration Allows Immediate Dose Adaptation , 2016, Clinical and translational gastroenterology.

[47]  K. Farkas,et al.  Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis. , 2016, Journal of Crohn's & colitis.

[48]  A. Gonçalves,et al.  Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point‐of‐care quantitative test with two established ELISA assays , 2016, Alimentary pharmacology & therapeutics.

[49]  P. Rutgeerts,et al.  Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies , 2016, Journal of Crohn's & colitis.

[50]  S. Vermeire,et al.  Generation and characterization of a unique panel of anti-adalimumab specific antibodies and their application in therapeutic drug monitoring assays. , 2016, Journal of pharmaceutical and biomedical analysis.

[51]  R. Baldassano,et al.  Serum Infliximab, Antidrug Antibodies, and Tumor Necrosis Factor Predict Sustained Response in Pediatric Crohn's Disease , 2016, Inflammatory bowel diseases.

[52]  P. Rutgeerts,et al.  Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[53]  S. Vermeire,et al.  Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples , 2016, Inflammatory bowel diseases.

[54]  S. Marshall,et al.  Good Practices in Model‐Informed Drug Discovery and Development: Practice, Application, and Documentation , 2016, CPT: pharmacometrics & systems pharmacology.

[55]  C. Ponsioen,et al.  Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[56]  S. Vermeire,et al.  An Optimized Anti-infliximab Bridging Enzyme-linked Immunosorbent Assay for Harmonization of Anti-infliximab Antibody Titers in Patients with Inflammatory Bowel Diseases , 2015, Inflammatory bowel diseases.

[57]  Els Brouwers,et al.  Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays , 2015, Therapeutic drug monitoring.

[58]  H. Ogata,et al.  First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis , 2015, Journal of Gastroenterology.

[59]  K. Van Steen,et al.  Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. , 2015, Gastroenterology.

[60]  S. Wicha,et al.  TDMx: a novel web-based open-access support tool for optimising antimicrobial dosing regimens in clinical routine. , 2015, International journal of antimicrobial agents.

[61]  P. Rutgeerts,et al.  Factors associated with short- and long-term outcomes of therapy for Crohn's disease. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[62]  P. Rutgeerts,et al.  Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. , 2014, Gastroenterology.

[63]  W. Sandborn,et al.  Proactive Therapeutic Concentration Monitoring of Infliximab May Improve Outcomes for Patients with Inflammatory Bowel Disease: Results from a Pilot Observational Study , 2014, Inflammatory bowel diseases.

[64]  Els Brouwers,et al.  Development of a Universal Anti-Adalimumab Antibody Standard for Interlaboratory Harmonization , 2014, Therapeutic drug monitoring.

[65]  O. Dewit,et al.  Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[66]  P. Rutgeerts,et al.  Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial , 2014, Gut.

[67]  L. A. Christensen,et al.  Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial , 2013, Gut.

[68]  H. Tanke,et al.  A rapid assay for on-site monitoring of infliximab trough levels: a feasibility study , 2013, Analytical and Bioanalytical Chemistry.

[69]  Edgar Ramiterre,et al.  A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study , 2013, Annals of the rheumatic diseases.

[70]  Sergio Gutierrez-Ureña,et al.  A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study , 2013, Annals of the rheumatic diseases.

[71]  L. Peyrin-Biroulet,et al.  Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease: A Prospective Study , 2013, Inflammatory bowel diseases.

[72]  R. Eliakim,et al.  Clinical utility of antihuman lambda chain‐based enzyme‐linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti‐infliximab antibodies , 2012, Inflammatory bowel diseases.

[73]  Michael G Tovey,et al.  Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFα antagonists. , 2011, Journal of immunological methods.

[74]  R. Gearry,et al.  Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease , 2011, Inflammatory bowel diseases.

[75]  M. Dubinsky,et al.  A Cost-Effectiveness Analysis of Alternative Disease Management Strategies in Patients with Crohn's Disease Treated with Azathioprine or 6-Mercaptopurine , 2005, The American Journal of Gastroenterology.

[76]  P. Rutgeerts,et al.  Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. , 2003, Gastroenterology.

[77]  L. Denson,et al.  Development of Infliximab Target Concentrations During Induction in Pediatric Crohn Disease Patients. , 2019, Journal of pediatric gastroenterology and nutrition.

[78]  S. Vermeire,et al.  Golimumab Dried Blood Spot Analysis (GOUDA): a Prospective Trial Showing Excellent Correlation with Venepuncture Samples and More Detailed Pharmacokinetic Information , 2018, The AAPS Journal.

[79]  M. Dubinsky,et al.  Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients , 2016, The AAPS Journal.

[80]  R. Eliakim,et al.  Association of Induction Infliximab Levels With Clinical Response in Perianal Crohn's Disease. , 2016, Journal of Crohn's & colitis.

[81]  T. Buclin,et al.  Benchmarking Therapeutic Drug Monitoring Software: A Review of Available Computer Tools , 2012, Clinical Pharmacokinetics.